Spatial localization in multi-voxel spectroscopy depends on magnetic field gradients and frequency-encoded signals. The gradients separate tissue positions, while signal frequencies allow metabolite information to be assigned across a grid rather than treated as one undifferentiated sample. This spatial organization makes it possible to compare biochemical patterns between neighboring regions during one examination.
Metabolite peaks provide biochemical markers rather than direct anatomical images. In the spectra, choline, creatine, and N-acetylaspartate are examples of signals whose relative presence across voxels can reveal differences between tissue regions. Mapping these peaks spatially helps identify where biochemical abnormalities are concentrated, rather than relying only on the appearance of a lesion.
Disease-related biochemical change may vary within the same visible lesion. Multi-voxel measurements preserve this regional variation, so abnormal and comparatively healthy tissue can be evaluated within the same metabolic map. That distinction is important when structural MRI alone does not show the full extent or internal diversity of disease.
Anatomical MRI shows structure, whereas multi-voxel spectroscopy adds spatially mapped chemical information. The two approaches therefore answer different questions: MRI demonstrates what tissue looks like, while spectroscopy indicates how metabolite signals differ across that tissue. Used together, they can provide a more informative assessment than structural appearance alone.
A typical examination generates a grid of localized spectra from multiple spatially distinct tissue volumes during one scan. Magnetic field gradients and frequency encoding assign signals to their respective voxel locations, after which metabolite peaks can be compared across the grid. The resulting map is interpreted alongside anatomical MRI to relate biochemical patterns to tissue structure.
Clinicians may use the method when a brain lesion requires metabolic characterization in addition to anatomical imaging. Comparing spectra from lesion and nearby tissue can show biochemical differences that support assessment of abnormal tissue. Its value is greatest when spatially varied metabolism matters, because one localized measurement could miss regional differences represented elsewhere in the lesion.
Metabolic maps can contribute to biopsy or treatment planning by showing where biochemical abnormalities are distributed within a lesion. This information adds a spatially resolved layer to anatomical targeting, helping teams consider whether different parts of the lesion have different metabolic profiles. The approach does not replace structural imaging; it complements it when planning must account for tissue variation.
Repeated metabolic mapping can support monitoring response to therapy by comparing metabolite patterns across examinations. Because the technique records multiple voxels, follow-up assessment can consider whether biochemical differences remain spatially localized or vary across the tissue. This complements anatomical follow-up when structural appearance alone may not capture treatment-related metabolic change.